KAM
HZNP

Knightsbridge Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Knightsbridge Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-54,945
Closed -$6.36M – 129
2023
Q3 		$6.36M Sell
54,945
-239
-0.4% -$25.7K 2% 14
2023
Q2 		$5.68M Buy
+55,184
New +$5.82M 1.83% 23

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Knightsbridge Asset Management's HZNP Position: Q4 2023 in Review

Knightsbridge Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 54,945 shares — an estimated $6.36M sold.

Knightsbridge Asset Management first reported a position in HZNP in Q2 2023 and held it in 2 quarters. The position peaked at $6.36M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Knightsbridge Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Knightsbridge Asset Management sold 54,945 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $6.36M.
  • Knightsbridge Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 2 quarters.
  • Knightsbridge Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.36M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Knightsbridge Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.